Eli Lilly to acquire Merida Biosciences for up to $2.875B
Eli Lilly has agreed to acquire biotechnology company Merida Biosciences for up to $2.875 billion in cash, a deal that expands the drugmaker's autoimmune and allergy pipeline. Merida's lead drug MER511 is in Phase 1 for Graves' disease and thyroid eye disease.
Detected & updated continuously · Source: Nebula
Story subjects
Sources
@IPONewsroom_
$LLY TO BUY MERIDA BIOSCIENCES FOR UP TO $2.875B Eli Lilly is acquiring Merida to expand its autoimmune and allergy pipeline. Merida’s lead drug, MER511, is in Phase 1 for Graves’ disease and thyroid eye disease, while its platform is designed to selectively remove https://t.co/YSkfrXDWcS
@blckchaindaily
🚨 ELI LILLY $LLY TO ACQUIRE MERIDA BIOSCIENCES FOR UP TO $2.875B IN CASH
@WSJ
Eli Lilly has agreed to pay up to $2.875 billion in cash for biotechnology company Merida Biosciences in a deal that bolsters the drugmaker’s immunology portfolio. https://t.co/Tnolx5BPvG